特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
951323

COVID-19 (新型コロナウイルス感染症) - ワクチンの治療パイプライン:2020年

COVID-19 (Novel Coronavirus 19) - Therapeutic Pipeline for Vaccines - 2020

出版日: | 発行: DelveInsight Business Research LLP | ページ情報: 英文 111 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.15円
COVID-19 (新型コロナウイルス感染症) - ワクチンの治療パイプライン:2020年
出版日: 2020年07月01日
発行: DelveInsight Business Research LLP
ページ情報: 英文 111 Pages
納期: 即日から翌営業日
担当者のコメント
COVID-19のワクチンの最新パイプライン動向をまとめた調査レポートが、臨床分野での調査に精通したDelveInsight社よりリリースされました。約60の製品動向に着目し、詳細なパイプライン分析を行っております。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、COVID-19 (新型コロナウイルス感染症) パイプライン情勢について調査分析し、50社以上の企業と60以上のワクチン関連製品に関する考察について、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 主な考察

第3章 疾患の背景と概要:COVID-19

  • イントロダクション
  • コロナウイルスの分類
  • SARS-CoV-2(COVID-19)の遺伝的構造と病原性メカニズム
  • 危険因子
  • 感染様式
  • 兆候と症状
  • 病因

第4章 新興の治療

  • ワクチン
    • Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)
    • mRNA-1273 vaccine
    • Matrix-M
    • Virus-Like Particle (VLP) Based Vaccine
    • Coronavirus vaccine INO-4800
    • BNT162

第5章 治療の評価

  • パイプライン薬の臨床評価
    • 評価:開発段階別
    • 評価:投与経路別
    • 評価:ワクチンの種類別

第6章 COVID-19:DelveInsightによる視点

  • 詳細な商業的評価
  • COVID-19 提携取引

第7章 COVID-19に対するその他の新興パイプライン治療オプション

  • モノクローナル抗体
  • その他の生物製剤
  • 低分子
  • その他

第8章 主要動向と発展

第9章 SWOT分析

第10章 市場促進要因

第11章 市場の障壁

第12章 アンメットニーズ

第13章 付録

第14章 調査手法

章15章 DelveInsightのサービス内容

第16章 免責事項

第17章 DelveInsightについて

図表

List of Tables

  • Table 1 Total Vaccine Products for COVID 19
  • Table 2 Assessment by Route of Administration
  • Table 3 Assessment by Stage and Route of Administration
  • Table 4 Assessment by Vaccine Type
  • Table 5 Assessment by Stage and Vaccine Type
  • Table 6 COVID-19 companies' collaborations, Licensing, Acquisition -Deal Value Trends
  • Table 7 COVID-19 Collaboration Deals
  • Table 8 Company-Company Collaborations (Licensing / Partnering) Analysis
  • Table 9 Company-University Collaborations (Licensing / Partnering) Analysis
  • Table 10 Market Drivers and Barriers
  • Table 11 SWOT Analysis
  • Table 12 Unmet Needs

List of Figures

  • Figure 1 Total Vaccine Products for COVID 19
  • Figure 2 Assessment by Route of Administration
  • Figure 3 Assessment by Stage and Route of Administration
  • Figure 4 Assessment by Vaccine Type
  • Figure 5 Assessment by Stage and Vaccine Type
  • Figure 6 COVID-19 companies' collaborations, Licensing, Acquisition -Deal Value Trends
  • Figure 7 COVID-19 Collaboration Deals
  • Figure 8 Company-Company Collaborations (Licensing / Partnering) Analysis
  • Figure 9 Company-University Collaborations (Licensing / Partnering) Analysis
  • Figure 10 Market Drivers and Barriers
  • Figure 11 SWOT Analysis
  • Figure 12 Unmet Needs
目次
Product Code: DICL0011A

DelveInsight's 'COVID-19 (Novel Coronavirus 19) - Therapeutic Pipeline for Vaccines - 2020' report provides comprehensive insights about 50+ companies and 60+ Vaccine based products in Covid-19 pipeline landscape. It covers the pipeline vaccine profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Understanding

COVID-19 (Novel Coronavirus 19) and Therapeutic Vaccines: Overview

The pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China in December 2019 is a highly contagious disease. The World Health Organization (WHO) has declared the ongoing outbreak as a global public health emergency. Currently, the research on novel coronavirus is still in the primary stage. In late December 2019, a case of unidentified pneumonia was reported in Wuhan, Hubei Province, People's Republic of China (PRC). Its clinical characteristics are very similar to those of viral pneumonia. After analysis on respiratory samples, PRC Centers for Disease Control (CDC) experts declared that the pneumonia, later known as novel coronavirus pneumonia (NCP), was caused by novel coronavirus.

To date, there is no approved targeted treatment, and many investigational therapeutic agents and vaccine candidates are being considered for the treatment of COVID-19. The availability of a safe and effective vaccine for COVID-19 is well-recognized as an additional tool to contribute to the control of the pandemic. At the same time, the challenges and efforts needed to rapidly develop, evaluate and produce this at scale are enormous. It is vital that as many vaccines as possible are evaluated as it cannot be predicted how many will turn out to be viable.

To increase the chances of success (given the high level of attrition during vaccine development), all candidate vaccines must be tested until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development.

COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Emerging Vaccines Chapters

This segment of the COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines report encloses its detailed analysis of various vaccines in different stages of clinical development, including phase III, I/II, and I. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included vaccine, and the latest news and press releases.

COVID-19 (Novel Coronavirus 19) Therapeutic Emerging Vaccines

  • INO-4800: Inovio Pharmaceuticals

Inovio Pharmaceuticals has begun human clinical trials on their coronavirus vaccine INO-4800 in April 2020. Results from the clinical trials are expected to be available in September 2020. Inovio aims to produce one million doses of the vaccine by the end of 2020 to perform additional clinical trials and/or emergency use of the vaccine. In 10 weeks from funding, INOVIO has manufactured thousands of doses of INO-4800 to support on-going Phase 1 and planned Phase II clinical trials. In parallel, INOVIO is working to scale up the manufacturing of INO-4800. INOVIO plans to have one million doses of the vaccine available by year-end for additional trials and emergency use, pending appropriate regulatory guidance and funding.

  • Ad5-nCoV: CanSino Biologics Inc.

CanSino Biologics Inc. is developing Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) candidate Ad5-nCoV in phase II stage of development for the treatment of COVID-19. It is co-developed with Beijing Institute of Biotechnology (BIB). It is currently the first novel coronavirus vaccine for COVID-19 that made to this stage in China. The vaccine candidate is built upon CanSinoBIO's adenovirus-based viral vector vaccine technology platform, which has also been successfully applied to develop the globally innovative vaccine against Ebola virus infection. Results from preclinical animal studies of Ad5-nCoV show that the vaccine candidate can induce strong immune response in animal models. The preclinical animal safety studies demonstrated a good safety profile.

  • mRNA-1273 Vaccine: Moderna Inc.

mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. The Coalition for Epidemic Preparedness Innovations (CEPI) supported the manufacturing of the vaccine candidate for the Phase II clinical trial. This investigational vaccine was developed using messenger RNA (mRNA) and should direct the body's cells to express a virus protein that hopefully will elicit a robust immune response, having shown promise in animal models.

  • VTP-500: Vaccitech

Vaccitech's VTP-500 MERS vaccine utilizes the ChAdOx1 virus platform to encode MERS coronavirus spike protein in order to induce T cells, but also antibodies which block virus-host cell receptor binding and fusion or neutralize virus infection. This program has been partnered with University Of Oxford, Janssen and CEPI. The vaccine has now been manufactured according to GMP practice and has been successfully tested in a Phase 1 clinical trial at Oxford University. CEPI, Oxford University and Janssen have entered into a collaboration worth up to $19M to progress the vaccine through Phase 2 studies and establish a human vaccine stockpile. Vaccitech retains commercial rights for the product while licensing certain rights back to Oxford for non-profit development of the vaccine.

  • V-SARS: Immunitor

Immunitor is developing therapeutic vaccine V-SARS which is formulated as a pill derived from heat-inactivated plasma from COVID-19 patients administered once-per-day to at least 20 healthy volunteers for at least one month. It is currently in phase I/II stage of development.

In May 2020, Immunitor initiated phase I/II trial titled "clinical trial of COVID-19 therapeutic vaccine formulated as an oral pill". The goal of this trial is test safety and immunogenicity of once-per-day day administered orally to volunteers for 15 days. Baseline and post-treatment standard safety parameters will be compared. Blood samples from volunteers will be monitored and immunogenicity lab assays will be undertaken to characterize immune response. The trial is currently in active, not recruiting stage with estimated enrollment of 20 participants and expected to be completed in June 2021.

  • SARS-CoV-2 rS Nanoparticle Vaccine: Novavax

Novavax is developing SARS-CoV-2 rS nanoparticle vaccine for the treatment of patients with COVID-19 infections. 2019nCoV-101 is a 2-part, randomized, observer-blinded, placebo-controlled, Phase 1/2 trial designed to evaluate the immunogenicity and safety of SARS-CoV-2 rS nanoparticle vaccine with or without Matrix-M adjuvant in healthy participants ≥ 18 to 59 (inclusive) years of age. The study will be conducted in 2 parts. In Part 1, at least 1 and up to two SARS-CoV-2 rS constructs will be evaluated in up to 2 cohorts, which may be enrolled in parallel.

An interim analysis of Part 1 safety and immunogenicity data will be performed prior to an optional expansion to Part 2. This trial is expected to be completed by July 2021.

Further product details are provided in the report…

COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines: Therapeutic Assessment

This segment of the report provides insights about the different Covid-19 emerging vaccines segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Covid-19 Vaccines

There are approx. 50+ key companies which are developing the therapies for Covid-19. The companies which have their Covid-19 vaccine candidates in the most advanced stage, i.e. Phase-III, include, Verity Pharmaceuticals and Immodulon Therapeutics Ltd.

  • Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II) and
  • Early-stage products (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intramuscular
  • Oral
  • Intravenous
  • Subcutaneous etc.
  • Type of Vaccines

Vaccines have been categorized under various types such as

  • Adenovirus based vaccine
  • Allogeneic cellular vaccine
  • Bacterial Vaccine
  • Combination adjuvant
  • DNA vaccine
  • Heat-killed Mycobacterium
  • Inactivated virus
  • Inactivated virus, plus adjuvant
  • Modified APC
  • mRNA vaccine
  • Peptide vaccine
  • Protein-Based Vaccines
  • Recombinant Bacterial Vaccine (Live-attenuated)
  • Recombinant protein vaccines
  • Recombinant Viral vaccines
  • Vero-cell based Vaccine
  • Virus Based Vaccine
  • Virus-like particle vaccines

COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, and Phase I/II stage. It also analyses COVID-19 (Novel Coronavirus 19) therapeutic vaccines key players involved in developing key vaccines.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 (Novel Coronavirus 19) therapeutic Vaccines.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in COVID-19 (Novel Coronavirus 19) therapeutic vaccines domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Report Highlights:

  • In the coming years, COVID-19 (Novel Coronavirus 19) therapeutic vaccines market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the vaccine manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 (Novel Coronavirus 19) therapeutic vaccines R&D. The therapies under development are focused on novel approaches to treat/improve Covid-19 infection.
  • Around the globe, approx. 150 vaccine candidates (Both academics & industries) are currently under development, in which most of the vaccines are in pre-clinical stage. However, there are approx. 60 clinical vaccine based products of industries under clinical and pre-clinical studies currently.
  • The players have adopted multiple approaches for the development of vaccines. Some of the approaches adopted by the companies include, whole virus vaccines, subunit vaccines, and nucleic acid based vaccines.
  • A significant number of interventional clinical trials are being conducted in China. In addition, a number of trials have recently been initiated in the US and several European countries.
  • There are multiple leading research institutes that have received NIH grants for research on coronavirus. Some of the leading academic institutes include, University of North Carolina, University of Iowa, University of Pennsylvania, University of Texas and University of Colorado.
  • INOVIO's DNA Medicines Platform is one-of-a-kind platform delivers optimized DNA into cells, where it is translated into proteins that activate an individual's immune system to generate a robust targeted T cell and antibody response. CELLECTRA uses a brief electrical pulse to open small pores in the cell reversibly to allow the plasmids to enter. Once inside the cell, the plasmids begin replicating, thereby strengthening the body's own natural response mechanisms.
  • Symvivo's bacTRL platform technology is a genetically-modified probiotic bacteria. Used as a single dose and administered intravenously or orally, bacTRL selectively colonizes hypoxic tissue while simultaneously being cleared from healthy tissues.Throughout the life of the colony, the bacteria produce and deliver genetic material to the surrounding tissues, providing consistent and progressive levels of gene delivery and expression.
  • On January 30, 2020, Beijing Advaccine Biotechnology announced a collaboration with Inovio Pharmaceuticals, Inc. to advance the development in China of the INO-4800 vaccine candidate, which is targeted against the novel coronavirus named 2019-nCoV.
  • On April 6, 2020 - INOVIO Pharmaceuticals, Inc. announced that the U.S. FDA has accepted the company's Investigational New Drug application for INO-4800, its DNA vaccine candidate designed to prevent COVID-19 infection, paving the way for Phase I clinical testing of INO-4800 in healthy volunteers.
  • Vaccitech's vaccine candidate has now been manufactured according to GMP practice and has been successfully tested in a Phase 1 clinical trial at Oxford University. CEPI, Oxford University and Janssen have entered into a collaboration worth up to $19M to progress the vaccine through Phase 2 studies and establish a human vaccine stockpile. Vaccitech retains commercial rights for the product while licensing certain rights back to Oxford for non-profit development of the vaccine.
  • On March 27, 2020, the NIH announced that Emory University in Atlanta will begin enrolling healthy adult volunteers ages 18 to 55 years in the NIH-led Phase 1 study of mRNA-1273.

COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Report Insights

  • COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of upcoming Vaccines

COVID-19 (Novel Coronavirus 19) Therapeutic Vaccines Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • SWOT Analysis
  • Attribute Analysis

Key Questions:

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing COVID-19 (Novel Coronavirus 19) therapeutic vaccines?
  • How many COVID-19 (Novel Coronavirus 19) therapeutic vaccines are developed by each company?
  • How many emerging vaccines are in mid-stage, and late-stage of development for the treatment of COVID-19 (Novel Coronavirus 19)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the COVID-19 (Novel Coronavirus 19) therapeutic vaccines?
  • What are the recent trends, vaccine types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for COVID-19 (Novel Coronavirus 19) therapeutic vaccines and their status?
  • What are the key designations that have been granted to the emerging vaccines?

Table of Contents

1. Report Introduction

2. Key Insights

3. Disease Background and Overview: Coronavirus Disease 2019 (COVID-19)

  • 3.1. Introduction
  • 3.2. Classification of Coronavirus
  • 3.3. Genetic structure and pathogenic mechanism of SARS-CoV-2 (COVID 19)
  • 3.4. Risk Factors
  • 3.5. Modes of Transmission: implications for IPC precaution recommendations
    • 3.5.1. Droplet transmission
    • 3.5.2. Airborne transmission
  • 3.6. Signs and symptoms
  • 3.7. Pathogenesis

4. Emerging Therapeutics

  • 4.1. Vaccines
    • 4.1.1. Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector): CanSino Biologics Inc.
      • 4.1.1.1. Vaccine Description
      • 4.1.1.2. Regulatory Milestones
      • 4.1.1.3. Clinical Development
      • 4.1.1.4. Product Profile
      • 4.1.1.5. Clinical Pipeline Activity
      • 4.1.1.5.1. Ongoing Trials Information
      • 4.1.1.5.2. Clinical Trials by Phase
      • 4.1.1.5.3. Safety and Efficacy
    • 4.1.2. mRNA-1273 vaccine: Moderna
      • 4.1.2.1. Vaccine Description
      • 4.1.2.2. Regulatory Milestones
      • 4.1.2.3. Clinical Development
      • 4.1.2.4. Product Profile
      • 4.1.2.5. Clinical Pipeline Activity
      • 4.1.2.5.1. Ongoing Trials Information
      • 4.1.2.5.2. Clinical Trials by Phase
      • 4.1.2.5.3. Safety and Efficacy
    • 4.1.3. Matrix-M: Novavax
      • 4.1.3.1. Vaccine Description
      • 4.1.3.2. Regulatory Milestones
      • 4.1.3.3. Clinical Development
      • 4.1.3.4. Product Profile
      • 4.1.3.5. Clinical Pipeline Activity
      • 4.1.3.5.1. Ongoing Trials Information
      • 4.1.3.5.2. Clinical Trials by Phase
      • 4.1.3.5.3. Safety and Efficacy
    • 4.1.2. mRNA-1273 vaccine: Moderna
      • 4.1.2.1. Vaccine Description
      • 4.1.2.2. Regulatory Milestones
      • 4.1.2.3. Clinical Development
      • 4.1.2.4. Product Profile
      • 4.1.2.5. Clinical Pipeline Activity
      • 4.1.2.5.1. Ongoing Trials Information
      • 4.1.2.5.2. Clinical Trials by Phase
      • 4.1.2.5.3. Safety and Efficacy
    • 4.1.3. Matrix-M: Novavax
      • 4.1.3.1. Vaccine Description
      • 4.1.3.2. Regulatory Milestones
      • 4.1.3.3. Clinical Development
      • 4.1.3.4. Product Profile
      • 4.1.3.5. Clinical Pipeline Activity
      • 4.1.3.5.1. Ongoing Trials Information
      • 4.1.3.5.2. Clinical Trials by Phase
      • 4.1.3.5.3. Safety and Efficacy
    • 4.1.4. Virus-Like Particle (VLP) Based Vaccine: Medicago
      • 4.1.4.1. Vaccine Description
      • 4.1.4.2. Regulatory Milestones
      • 4.1.4.3. Clinical Development
      • 4.1.4.4. Product Profile
      • 4.1.4.5. Clinical Pipeline Activity
      • 4.1.4.5.1. Ongoing Trials Information
      • 4.1.4.5.2. Clinical Trials by Phase
      • 4.1.4.5.3. Safety and Efficacy
    • 4.1.5. Coronavirus vaccine INO-4800: Inovio Pharmaceuticals
      • 4.1.5.1. Vaccine Description
      • 4.1.5.2. Regulatory Milestones
      • 4.1.5.3. Clinical Development
      • 4.1.5.4. Product Profile
      • 4.1.5.5. Clinical Pipeline Activity
      • 4.1.5.5.1. Ongoing Trials Information
      • 4.1.5.5.2. Clinical Trials by Phase
      • 4.1.5.5.3. Safety and Efficacy
    • 4.1.6. BNT162: BioNTech
      • 4.1.6.1. Vaccine Description
      • 4.1.6.3. Clinical Development
      • 4.1.6.4. Product Profile
      • 4.1.6.5. Clinical Pipeline Activity
      • 4.1.6.5.1. Ongoing Trials Information
      • 4.1.6.5.2. Clinical Trials by Phase
      • 4.1.6.5.3. Safety and Efficacy

List to be continued in the report…………………

5. Therapeutic Assessment

  • 5.1. Clinical Assessment of Pipeline Drugs
    • 5.1.1. Assessment by Phase of Development
    • 5.1.2. Assessment by Route of Administration
      • 5.1.2.1. Assessment by Stage and Route of Administration
    • 5.1.3. Assessment by Vaccine Type
      • 5.1.3.1. Assessment by Stage and Vaccine Type

6. COVID-19 - DelveInsight's Analytical Perspective

  • 6.1. In-depth Commercial Assessment
    • 6.1.1. COVID-19 companies' collaborations, Licensing, Acquisition -Deal Value Trends
  • 6.2. COVID-19 Collaboration Deals
    • 6.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    • 6.2.2. Company-University Collaborations (Licensing / Partnering) Analysis

7. Other Emerging Pipeline Therapeutic Options for Covid-19

  • 7.1. Monoclonal Antibodies
    • 7.1.1. Sarilumab: Regeneron Pharmaceuticals
    • 7.1.2. Tocilizumab (TCZ): Hoffmann-La Roche

List to be continued in the report…………………

  • 7.2. Other Biologics
    • 7.2.1. NestCell: Azidus Brasil

List to be continued in the report…………………

  • 7.3. Small Molecules
    • 7.3.1. Remdesivir: Gilead Sciences
    • 7.3.2. Hydroxychloroquine: Sanofi

List to be continued in the report…………………

  • 7.4. Others
    • 7.4.1. PUL-042 Inhalation Solution: Pulmotect, Inc.
    • 7.4.2. DAS181: Ansun Biopharma

List to be continued in the report…………………

8. Key Trends and Developments

9. SWOT Analysis

10. Market Drivers

11. Market Barriers

12. Unmet Needs

13. Appendix

14. Report Methodology

  • 14.1. Sources Used

15. DelveInsight Capabilities

16. Disclaimer

17. About DelveInsight

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.